We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
-7.49%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$211M
AUM Growth
-$127M
Cap. Flow
-$101M
Cap. Flow %
-47.95%
Top 10 Hldgs %
84.11%
Holding
64
New
9
Increased
4
Reduced
8
Closed
19

Top Buys

Rank Stock Value
1
TRDA icon
Entrada Therapeutics
TRDA
+$1.86M
2
REPL icon
Replimune Group
REPL
+$1.41M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$1.01M
4
TSVT
2seventy bio
TSVT
+$683K
5
AFMD
Affimed
AFMD
+$353K

Top Sells

Rank Stock Value
1
NFH
New Frontier Health Corporation Ordinary Shares
NFH
+$95.7M
2
NFH.WS
New Frontier Health Corporation Warrants, each whole warrant exercisable for one Ordinary Share at a
NFH.WS
+$4.27M
3
TVTX icon
Travere Therapeutics
TVTX
+$1.5M
4
ASND icon
Ascendis Pharma A/S
ASND
+$977K
5
BLUE
bluebird bio
BLUE
+$783K

Sector Composition

Rank Sector Weight
1 Healthcare 98.98%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ILMN icon
1
Illumina
ILMN
$31B
$45.3M 21.48%
133,277
– –
HRMY icon
2
Harmony Biosciences
HRMY
$2.04B
$37.4M 17.74%
768,708
– –
KRTX
3
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$29.8M 14.12%
234,811
– –
EAR
4
DELISTED
Eargo, Inc. Common Stock
EAR
$15.3M 7.24%
144,336
– –
SLGC
5
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$13.6M 6.45%
1,696,558
– –
EXAI
6
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$11.1M 5.26%
770,200
– –
SGEN
7
DELISTED
Seagen Inc. Common Stock
SGEN
$6.78M 3.22%
47,096
+1,756
+4% +$238K
RANI icon
8
Rani Therapeutics
RANI
$87M
$6.66M 3.16%
493,584
– –
XENE icon
9
Xenon Pharmaceuticals
XENE
$6.06B
$6.05M 2.87%
197,880
– –
VIR icon
10
Vir Biotechnology
VIR
$1.46B
$5.42M 2.57%
210,563
– –
BOLT icon
11
Bolt Biotherapeutics
BOLT
$7.67M
$3.2M 1.52%
58,348
– –
BEAM icon
12
Beam Therapeutics
BEAM
$2.63B
$3.15M 1.49%
54,903
– –
INCY icon
13
Incyte
INCY
$24.2B
$2.73M 1.3%
34,391
-119
-0.3% -$8.66K
ONC
14
BeOne Medicines Ltd
ONC
$32.8B
$2.27M 1.08%
12,022
+817
+7% +$174K
OTIC
15
DELISTED
Otonomy, Inc.
OTIC
$2.04M 0.97%
851,080
+80
+0% +$170
SRRA
16
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.7M 0.81%
52,979
– –
TRDA icon
17
Entrada Therapeutics
TRDA
$264M
$1.63M 0.77%
+173,582
New +$1.86M
GRTX
18
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$1.46M 0.69%
613,223
– –
EXEL icon
19
Exelixis
EXEL
$13.3B
$1.46M 0.69%
64,200
– –
PACB icon
20
Pacific Biosciences
PACB
$435M
$1.32M 0.63%
144,840
-26,920
-16% -$310K
REPL icon
21
Replimune Group
REPL
$941M
$1.26M 0.6%
+74,479
New +$1.41M
NVTA
22
DELISTED
Invitae Corporation
NVTA
$1.24M 0.59%
156,004
-1,858
-1% -$18.7K
EXAS
23
DELISTED
Exact Sciences
EXAS
$1.22M 0.58%
17,464
– –
KALV
24
DELISTED
KalVista Pharmaceuticals
KALV
$1.16M 0.55%
78,720
– –
CCXI
25
DELISTED
ChemoCentryx, Inc.
CCXI
$898K 0.43%
+35,830
New +$1.01M
1
2 3

Similar funds

TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Nan Fung Group Holdings's Q1 2022 Portfolio in Review

As of Q1 2022, Nan Fung Group Holdings held 64 positions worth $211M, down 38% from $338M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Nan Fung Group Holdings withdrew a net $101M in Q1 2022, closing 19 positions and reducing 8 holdings. Its most notable exit was New Frontier Health Corporation Ordinary Shares, an estimated $95.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 70% a quarter earlier, followed by Financials.

Against the trend, Nan Fung Group Holdings opened a new position in Entrada Therapeutics worth $1.63M.

  • Nan Fung Group Holdings's largest Q1 2022 buy was Entrada Therapeutics: 173,582 shares worth $1.63M.
  • Nan Fung Group Holdings added most to Kodiak Sciences in Q1 2022, an estimated $241K increase.
  • Nan Fung Group Holdings's biggest Q1 2022 reduction was Ascendis Pharma A/S, cutting an estimated $977K.
  • Nan Fung Group Holdings fully exited New Frontier Health Corporation Ordinary Shares in Q1 2022, selling an estimated $95.7M.
  • Nan Fung Group Holdings's ten largest holdings make up 84% of its $211M portfolio in Q1 2022.
  • Nan Fung Group Holdings opened 9 new positions and closed 19 in Q1 2022.
  • Nan Fung Group Holdings's portfolio value fell 38% quarter-over-quarter to $211M.

Based on Nan Fung Group Holdings's 13F filing for Q1 2022, filed 13 May 2022.